IMMUNOGEN INC Form 8-K August 31, 2005

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

# PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 30, 2005

# ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

Massachusetts (State or other jurisdiction of incorporation) **0-17999** (Commission File Number)


**04-2726691** (IRS Employer Identification No.)

128 Sidney Street, Cambridge, MA 02139

(Address of principal executive offices) (Zip Code)

Registrant s telephone number, including area code: (617) 995-2500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



#### ITEM 8.01 OTHER EVENTS

On August 31, 2005, ImmunoGen, Inc. (Nasdaq: IMGN) announced that Aventis Pharmaceuticals, Inc. of the sanofi-aventis Group has exercised its right to extend the term of its research collaboration with the Company, and committed to pay ImmunoGen a minimum of \$18.2 million in research support over the twelve months beginning September 1, 2006. This funding is in addition to the \$50.7 million in research support already committed for the three-year period ending August 31, 2006.

A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

#### ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.	Exhibit
99.1	Press Release of ImmunoGen, Inc. dated August 31, 2005

2

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ImmunoGen, Inc.

(Registrant)

Date: August 31, 2005 /s/ Karleen M. Oberton

Karleen M. Oberton Senior Corporate Controller (Principal Accounting Officer)

3